DE60134645D1 - Amidinderivate als selektive nmda-rezeptorantagonisten - Google Patents
Amidinderivate als selektive nmda-rezeptorantagonistenInfo
- Publication number
- DE60134645D1 DE60134645D1 DE60134645T DE60134645T DE60134645D1 DE 60134645 D1 DE60134645 D1 DE 60134645D1 DE 60134645 T DE60134645 T DE 60134645T DE 60134645 T DE60134645 T DE 60134645T DE 60134645 D1 DE60134645 D1 DE 60134645D1
- Authority
- DE
- Germany
- Prior art keywords
- nmda receptor
- receptor antagonists
- amidine derivatives
- selective nmda
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title abstract 2
- 150000001409 amidines Chemical class 0.000 title 1
- GDYXPZCCNRBQNS-VOTSOKGWSA-N (e)-3-phenylprop-2-enimidamide Chemical class NC(=N)\C=C\C1=CC=CC=C1 GDYXPZCCNRBQNS-VOTSOKGWSA-N 0.000 abstract 1
- 206010003591 Ataxia Diseases 0.000 abstract 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical class CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000001977 ataxic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015488.0A GB0015488D0 (en) | 2000-06-23 | 2000-06-23 | Therapeutic agents |
| PCT/GB2001/002621 WO2001098262A1 (en) | 2000-06-23 | 2001-06-14 | Amidine derivatives as selective antagonists of nmda receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60134645D1 true DE60134645D1 (de) | 2008-08-14 |
Family
ID=9894319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60134645T Expired - Lifetime DE60134645D1 (de) | 2000-06-23 | 2001-06-14 | Amidinderivate als selektive nmda-rezeptorantagonisten |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1296940B1 (de) |
| JP (1) | JP2004501136A (de) |
| AT (1) | ATE399762T1 (de) |
| AU (2) | AU6411601A (de) |
| CA (1) | CA2412164C (de) |
| DE (1) | DE60134645D1 (de) |
| GB (1) | GB0015488D0 (de) |
| WO (1) | WO2001098262A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| US7423149B2 (en) * | 2003-12-23 | 2008-09-09 | Schering Corporation | Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders |
| HUP0401523A3 (en) * | 2004-07-29 | 2007-05-02 | Richter Gedeon Vegyeszet | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
| KR20080035294A (ko) * | 2006-10-19 | 2008-04-23 | 한국과학기술연구원 | 1,2-디[2-메톡시-4-(2-카르복실비닐)]페녹시에탄 화합물을유효성분으로 함유하는 파킨슨병 예방 및 치료용 약학적조성물 |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| JP6042968B2 (ja) | 2012-04-20 | 2016-12-14 | ユセベ ファルマ ソシエテ アノニム | パーキンソン病の処置方法 |
| CN106905273B (zh) * | 2017-01-18 | 2019-05-14 | 中山大学 | 4-氧杂-4,5,6,7-四氢苯并[b]呋喃-3-羧酸类化合物及其应用 |
| EP3461819B1 (de) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Hemmer der glutaminylcyclase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3476768A (en) * | 1965-05-17 | 1969-11-04 | Pfizer & Co C | Thienylalanine |
| IL26870A (en) * | 1965-12-30 | 1971-01-28 | Pfizer | Imidazoline and tetrahydropyrimidine derivatives,their preparation and use |
| JPH10287637A (ja) * | 1997-04-14 | 1998-10-27 | Banyu Pharmaceut Co Ltd | アミジン誘導体 |
-
2000
- 2000-06-23 GB GBGB0015488.0A patent/GB0015488D0/en not_active Ceased
-
2001
- 2001-06-14 WO PCT/GB2001/002621 patent/WO2001098262A1/en active IP Right Grant
- 2001-06-14 AT AT01938439T patent/ATE399762T1/de not_active IP Right Cessation
- 2001-06-14 CA CA2412164A patent/CA2412164C/en not_active Expired - Fee Related
- 2001-06-14 AU AU6411601A patent/AU6411601A/xx active Pending
- 2001-06-14 DE DE60134645T patent/DE60134645D1/de not_active Expired - Lifetime
- 2001-06-14 JP JP2002504218A patent/JP2004501136A/ja not_active Withdrawn
- 2001-06-14 EP EP01938439A patent/EP1296940B1/de not_active Expired - Lifetime
- 2001-06-14 AU AU2001264116A patent/AU2001264116B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU6411601A (en) | 2002-01-02 |
| AU2001264116B2 (en) | 2006-04-13 |
| CA2412164C (en) | 2010-10-26 |
| JP2004501136A (ja) | 2004-01-15 |
| ATE399762T1 (de) | 2008-07-15 |
| EP1296940A1 (de) | 2003-04-02 |
| GB0015488D0 (en) | 2000-08-16 |
| EP1296940B1 (de) | 2008-07-02 |
| WO2001098262A1 (en) | 2001-12-27 |
| CA2412164A1 (en) | 2001-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE399762T1 (de) | Amidinderivate als selektive nmda- rezeptorantagonisten | |
| HK1049284B (zh) | 對疼痛受體具有親合力的苯並咪唑化合物 | |
| TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
| ZA200007694B (en) | EP4 receptor selective agonists in the treatment of osteoporosis. | |
| HK1068783A1 (en) | Methods for increasing the therapeutic response to electroconvulsive therapy ("ect") | |
| AU1327501A (en) | Device for delivering biological agents | |
| BR9813957A (pt) | Uso de antagonistas da vasopressina | |
| WO2004009616A3 (en) | Ghrelin analogs | |
| AU5338401A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| NO994850L (no) | Farmakologiske midler | |
| ES2112546T3 (es) | Benz(b)azepina-2,5-dionas utiles en el tratamiento de trastornos neurodegenerativos. | |
| WO2001039723A3 (en) | Triazospiro compounds having nociceptin receptor affinity | |
| AU2003274307A1 (en) | 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist | |
| ATE240303T1 (de) | 1,2,4-triazol-3-thion verbindungen | |
| AU6469401A (en) | Pharmaceutically active compounds and methods of use | |
| AU2002217668A1 (en) | Activity aid apparatus | |
| WO2002034240A3 (en) | Delayed and sustained release formulations and method of use thereof | |
| IL144199A0 (en) | Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
| NO996044D0 (no) | Rapamycinformuleringer for oral administrasjon | |
| MY127675A (en) | Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods | |
| IL156069A0 (en) | Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma | |
| ZA984838B (en) | Bacterial pheromones and uses therefor. | |
| ZA200205464B (en) | Device for preventing or relieving pain in the lower back. | |
| AU2001258442A1 (en) | Drug delivery device, especially for the delivery of levonorgestrel | |
| AU6846300A (en) | Use of cyamemazine for cold turkey benzodiazepine treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |